BlossomHill Therapeutics raises $150 million in upsized oncology IPO

Oncology-focused biotechnology firm BlossomHill Therapeutics Inc. raises $150 million in an upsized initial public offering on August 7, 2026. Although the company prices its IPO at $16 per share, marketing 7.8 million shares within a $15 to $17 range, its stock opens below that mark at $15.75 in New York. BlossomHill shares ultimately decline by 1.6% during their market debut, reflecting immediate post-IPO trading pressure.

BlossomHill Therapeutics IPO

• ▪BlossomHill Therapeutics Inc. is an oncology-focused biotechnology firm that launched its initial public offering on August 7, 2026.
• ▪BlossomHill Therapeutics Inc. raised $150 million in an upsized United States initial public offering on August 7, 2026.

Post-IPO stock performance

• ▪BlossomHill Therapeutics Inc. shares fell 1.6% during their trading debut in New York on August 7, 2026.
• ▪BlossomHill Therapeutics Inc. stock opened at $15.75 on August 7, 2026, which was below its initial public offering price.

IPO pricing details

• ▪BlossomHill Therapeutics Inc. priced its initial public offering at $16 per share.
• ▪BlossomHill Therapeutics Inc. marketed 7.8 million shares within an estimated price range of $15 to $17 each.

2 sources